ADAtakan Demir

Atakan Demir

*This is an algorithmically generated author record based on publicly available information.

Atakan Demir has a total of 184 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study

    by Omer Fatih Olmez, Ahmet Bilici, Ozlem Er, Atil Bisgin, Alper Sevinc, Tulay Akman, Ruchan Uslu, Nil Molinas Mandel, Suayib Yalcin, Mehmet Teomete, et al.

    The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes. The study encompassed 234 adult patients (mean age: 52.7 ± 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response. Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16). Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates.


  • Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

    by Ahmet Bilici, Mukremin Uysal, Serkan Menekse, Semih Akin, Fatih Yildiz, Merve Turan, Sema Sezgin Goksu, İsmail Beypinar, Teoman Sakalar, Mustafa Değirmenci, et al.

    PurposeThis tudy evaluated the efficacy and safety of everolimus plus exemestane (EVE + EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods: Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results: The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). Presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion: We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER2- MBC patients.


  • Identifying Knowledge and Practices regarding Cancer Patient Malnutrition: A Survey Study among Oncologists

    by Ozlem Sonmez, Evrim Tezcanli, Dilsat Bas, Hande Busra Kazanci, Ayse Altinok, Atakan Demir, Basak Oyan Uluc

    Malnutrition is one of the most common complications of cancer and its treatments with a prevalence of up to 80% among cancer patients. Thus, standardized and target-oriented attitudes of oncologists toward nutritional management are particularly important. This study aims to report the questionnaire-based evaluation of different views toward medical nutrition among medical and radiation oncologists with the purpose to underline the problems and requirements of cancer nutrition. A national web-based survey composed of 26 multiple choice questions about participant demographics, level of knowledge about cancer nutrition, and approaches to malnutrition were completed by 247 oncologists. The survey was answered by a total of 247 (34%) radiation and medical oncologists. The majority of the oncologists (77%) were working at the University Hospitals and Education & Research Hospitals. Most of them were specialists with 5-10 years of experience. Nutritional status was routinely assessed in oncology units of 84% of (206) oncologists. However, only 50% reported nutritional evaluation follow-ups without waiting for a patient’s declaration and 5 (2%) oncologists reported the absence of nutritional evaluation in their unit. Additionally, more than 79% of participants reported that their knowledge was not enough about enteral and parenteral nutrition while 8% were skeptical about the benefits of medical nutrition. Although the role of nutrition as an essential part of cancer care is widely recognized, the availability of limited high-quality evidence, problems of accessibility, lack of routine nutritional evaluation, and varying indicators for malnutrition are some of the problems preventing standardized nutritional management. Therefore, there are a variety of approaches and barriers to the implementation of guidelines. Further studies are needed to identify areas of improvement, as well as strategies to implement nutritional therapy in cancer care.


  • Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

    by Aykut Bahçeci, Semra Paydaş, Naziye Ak, Ferhat Ferhatoğlu, Pınar Mualla Saip, Gülşah Seydaoğlu, Mehmet Bilici, Melih Şimşek, Salim Başol Tekin, Züleyha Çalikuşu, et al.

    The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment.Retrospective analysis o...


  • Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

    by Mustafa Gürbüz, Erman Akkuş, Abdullah Sakin, Semiha Urvay, Atike Gökçen Demiray, Süleyman Şahin, Teoman Şakalar, Cihan Erol, Mehmet Ali Nahit Şendur, Ahmet Bilgehan Şahin, et al.

    Purpose In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab ± capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab ± capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7–51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2–30). The median PFS of the patients was 12.0 months (95% CI 10.3–13.7), and median OS was 17.4 months (95% CI 15.2–19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion Trastuzumab maintenance ± capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.


  • Is a Total Colectomy a Better Surgical Treatment for Spontaneous Colonic Perforation that Developed during Bevacizumab Treatment for Extra-intestinal Cancers?

    by Ege Baltacı, Atakan Demir, Bilgi Baca, Gökhan Demir, İsmail Hamzaoğlu, Volkan Özben, Afag Aghayeva, Ahmet İsMail Bilgin, Bahadır Osman Bozkırlı, Erman Aytaç, et al.


  • Worse patient–physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

    by Ali Alkan, Arzu Yaşar, Zeynep Gülsüm Güç, Mustafa Gürbüz, Tuğba Başoğlu, Sema Sezgin Göksu, Fatma Buğdaycı Başal, Hacı Mehmet Türk, Özlem Özdemir, Havva Yeşil Çınkır, et al.

    Objective Fear of cancer recurrence (FCR) is an important psychological trauma associated with reduction in the quality of life, disruptions in the level of adjustment, emotional distress and anxiety. The purpose of the study was to evaluate the impact of patient–physician relationship on FCR. Methods The study was designed as a multicentre survey study. The cancer survivors, who were under remission, were evaluated with structured questionnaires. Patient–physician relationship (PPR) scale in which higher scores indicate better relationship and FCR inventory was used. Results Between January and April 2019, 1,580 patients were evaluated. The median age was 57.0 (19–88), and 66% were female. There was high level of FCR scores in 51% of participants. There was a negative correlation between PPR and FCR scores (r = −.134, p < .001). In multivariate analysis, young age, female gender, history of metastasectomy and worse PPR were associated with high levels of FCR. Conclusion It is the first data showing the adverse impact of worse PPR on FCR. The strategies to improve the PPR should be practised. In addition, the cancer survivors, who are under the risk of FCR, should be evaluated and managed.


  • Predictive Values of Systemic Inflammation Index in Prognosis of Patients with Laryngeal Cancer

    by Atakan Demir, Ozkan Alan, Mehmet Surmeli

    Objectives: Laryngeal cancer is the most common cancer in head and neck cancer group, of which it constitutes 75%. Squamous cell carcinoma (SCC) is the most common histological subtype. Systemic or local inflammation is a well known promotor for cancer development and progression. Systemic immune inflammation index (S II) has been reported as an independent prognostic parameter in various cancers. We aimed to evaluate the capability of SII in predicting the risk of recurrence in patients with operable laryngeal cancer. Methods: We retrospectively collected the data of 100 laryngeal SCC patients who underwent surgery between 2016 and 2018. Neutrophil, lymphocyte, and platelet (Plt) counts were recorded. The SII was calculated as follows: SII= Neutrophile counts *platelet counts/lymphocyte counts. Results: SI index was found to be an independent prognostic factor as affecting disease recurrence (p891 had a risk of disease recurrence of approximately three times more than patients with SII = <891.78 (HR: 3.06 (95% CI: 3.42-132.64). Conclusion: This was the first study to demonstrate that preoperative SI index is a simple and powerful independent predictive index that predicts the risk of disease recurrence in patients with laryngeal cancer.

  • Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

    by Atakan Demir, Nil Molinas Mandel, Semra Paydas, Gökhan Demir, Özlem Er, Nazım Serdal Turhal, Sevil Bavbek, Yeşim Eralp, Pınar Mualla Saip, Emine Nilüfer Güler, et al.

    Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2- metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2- patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.


  • The impact of total neo-adjuvant treatment on nonoperative management in patients with locally advanced rectal cancer: The evaluation of 66 cases

    by Oktar Asoglu, Handan Tokmak, Baris Bakir, Gokhan Demir, Enis Ozyar, Banu Atalar, Suha Goksel, Burak Koza, Aslihan Guven Mert, Atakan Demir, et al.